Olanzapine has been used for the treatment of
schizophrenia and other
mental disorders. However, it is associated with serious
weight gain and other metabolic side-effects. The antagonistic affinity of
olanzapine to
muscarinic M3 receptors has been evidenced as one of the main contributors for its
weight gain and other metabolic side-effects. Therefore, this study investigated whether the co-treatment of
cevimeline (a M3 receptor agonist) could prevent the metabolic side-effects associated with
olanzapine medication. Female Sprague Dawley rats were treated orally with
olanzapine (2 mg/kg, t.i.d.) and/or
cevimeline at 3 dosages (3, 6, 9 mg/kg, t.i.d.), or vehicle for two weeks.
Weight gain and food/water intake were measured throughout the drug treatment period. Intraperitoneal
glucose tolerance tests and open field tests were conducted.
Olanzapine-treated rats demonstrated significantly elevated
body weight gain, food intake, feeding efficiency, total white fat mass, liver mass, and plasma
triglyceride levels, which could be partly reversed by the co-treatment with
cevimeline in a dosage-dependent manner. In general, the
body weight gain can only be reversed by the co-treatment of 9 mg/kg
cevimeline. The
cevimeline co-treatment decreased plasma
triglyceride and
glucose levels compared with
olanzapine only treatment. The results suggested a dosage-dependent effect of
cevimeline in ameliorating
olanzapine-induced
weight gain and metabolic side-effects, which supports further clinical trials using
cevimeline to control
weight gain and metabolic side-effects caused by
antipsychotic medications.